Medicenna Therapeutics (TSE:MDNA) Stock Price Down 18.2% – What’s Next?

Medicenna Therapeutics Corp. (TSE:MDNA) dropped 18.2% during mid-day trading on Thursday . The stock traded as low as C$0.51 and last traded at C$0.54. Approximately 193,189 shares traded hands during trading, an increase of 80% from the average daily volume of 107,333 shares. The stock had previously closed at C$0.66.

Medicenna Therapeutics Stock Performance

The stock has a market cap of C$47.55 million, a PE ratio of -3.80 and a beta of 2.90. The company has a fifty day moving average price of C$0.67 and a 200 day moving average price of C$0.97. The company has a quick ratio of 4.65, a current ratio of 2.68 and a debt-to-equity ratio of 3.30.

Medicenna Therapeutics (TSE:MDNA) last issued its earnings results on Thursday, April 30th. The company reported C($0.06) earnings per share for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. Analysts expect that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.